Search Result

Objectives: To evaluate the clinical efficacy and safety of Livomyn in NAFLD. Material and Methods: A prospective, interventional clinical study was conducted on 50 patients of both sexes, aged between 18-65 years, confirmed with NAFLD from clinical examination, laboratory tests, ultrasound findings, and who were willing to give informed consent. All patients received Livomyn at a dose of 1 tablet thrice daily for 8 weeks. All patients were evaluated at baseline,4 weeks, and 8 weeks for biochemical investigations [hs-CRP, TNF- ?, NF-?B, ALT, and AST (IU/L)]. Observation: Livomyn after 8 weeks, reduced inflammatory biomarkers including hs-CRP from 5647.1 ± 3858.4 to 4653.8 ± 4243.8; TNF-? from 19.34 ± 5.4 to 16.51 ± 4.5 (<0.001) and NF-?B from 2.07 ± 1.03 to 1.65 ± 0.63. Further Livomyn reduced elevated liver enzymes including ALT from 26.54 ± 15.46 to 20.82 ± 10.09 (<0.001) and AST from 17.78 ± 9.56 to 14.75 ± 7.45 (<0.001) after 8 weeks of treatment. Result: Livomyn produced a significant reduction in all the inflammatory/metabolic parameters associated with NAFLD assessed after 8 weeks of treatment. In addition, a significant improvement in Clinical Global Impression in efficacy and tolerability was also observed. No adverse events were reported by any patients. This indicates that Livomyn is clinically effective and safe for NAFLD.

Objectives: To evaluate the clinical efficacy and safety of Livomyn in NAFLD. Material and Methods: A prospective, interventional clinical study was conducted on 300 patients of both sexes, aged between 18-65 years, confirmed with NAFLD from clinical examination, laboratory tests, ultrasound findings, and who were willing to give informed consent. All patients received Livomyn at a dose of 1tabletthrice daily for 8 weeks. All patients were evaluated at baseline and 8 weeks for biochemical investigations [hs-CRP, TNF-?, NF-?B, ALT, and AST (IU/L)]. Observation: Livomyn after 8 weeks, reduced inflammatory biomarkers including hs-CRP from 6211.8 ± 4238.2to 5119.2 ± 4668.2; TNF-? from 21.27 ± 5.94to 18.16 ± 4.95 (<0.001) and NF-?B from 2.28 ± 1.13to 1.82 ± 0.69. Further Livomyn reduced elevated liver enzymes including ALT from 29.19 ± 17.01to 22.90 ± 11.09(<0.001) and AST from 19.56 ± 10.52 to 22.90 ± 11.09(<0.001) after 8 weeks of treatment. Livomyn significantly reduced Fibrosis from 7.68 ± 2.66 to 6.82 ± 2.62(<0.001) and Steatosisfrom328.19 ± 32.45 to 310.92 ± 44.10. compared to the baseline. Similar reductions were also observed in the positive (Pioglitazone) controlled group. But none of the changes were significantly different between two groups. Result: Livomyn produced a significant reduction comparable to the positive (Pioglitazone) controlled drug, in all the inflammatory/metabolic parameters associated with NAFLD assessed after 8 weeks of treatment. No adverse events were reported by any patients. This indicates that Livomyn is clinically effective and safe for NAFLD.